Introduction and Background

National Vaccination Day is observed annually on March 16 to commemorate the first administration of the Oral Polio Vaccine (OPV) in India’s Pulse Polio Programme in 1995. This day marks a pivotal moment in India’s public health history, symbolising the country’s commitment to eradicating vaccine-preventable diseases through systematic immunisation. The programme was launched by the Ministry of Health and Family Welfare (MoHFW) and has since evolved into a comprehensive national effort under the Universal Immunisation Programme (UIP), initiated in 1985.

Legal and Constitutional Framework Supporting Immunisation

India’s immunisation efforts are legally anchored in the Epidemic Diseases Act, 1897, particularly Section 2, which empowers states to implement special measures during epidemics. The National Vaccine Policy, 2011 provides strategic guidance on vaccine research, development, and deployment. The Universal Immunisation Programme (UIP), launched in 1985, serves as the primary operational framework to ensure vaccine coverage across demographics. Additionally, the Right to Health is interpreted under Article 21 of the Constitution as part of the Right to Life, reinforcing the state’s obligation to provide immunisation services.

• Epidemic Diseases Act, 1897: Enables state governments to enforce vaccination during outbreaks.
• National Vaccine Policy, 2011: Focuses on indigenous vaccine development and equitable access.
• Universal Immunisation Programme (UIP): Covers vaccines for tuberculosis, polio, diphtheria, pertussis, tetanus, measles, hepatitis B, and others.
• Article 21, Constitution of India: Judicial interpretations have expanded Right to Life to include access to healthcare and immunisation.

Economic Dimensions of India’s Vaccination Programme

India’s vaccine market was valued at approximately USD 3.6 billion in 2023 with a projected compound annual growth rate (CAGR) of 15% through 2030 (India Brand Equity Foundation, 2024). The Union Budget 2024-25 allocated ₹35,000 crore (~USD 4.3 billion) towards health and immunisation initiatives. India produced over 200 crore COVID-19 vaccine doses by 2023, supplying nearly 60% of global vaccine demand (WHO, 2023). The Pulse Polio Programme, costing about ₹1,000 crore annually during its peak, generated significant economic savings by averting polio-related healthcare expenses and productivity losses.

• Vaccine market size: USD 3.6 billion (2023), CAGR 15% till 2030.
• Government budget allocation: ₹35,000 crore for health and immunisation (2024-25).
• COVID-19 vaccine production: Over 200 crore doses by 2023, 60% of global supply.
• Pulse Polio cost-benefit: ₹1,000 crore annual cost vs. billions saved in healthcare.

Key Institutions and Their Roles in India’s Immunisation Ecosystem

The immunisation landscape involves multiple institutions coordinating policy, research, regulation, and manufacturing. The Ministry of Health and Family Welfare (MoHFW) formulates and implements immunisation policies. The Indian Council of Medical Research (ICMR) spearheads vaccine research and clinical trials. The Central Drugs Standard Control Organization (CDSCO) regulates vaccine approval and quality standards. The National Technical Advisory Group on Immunisation (NTAGI) provides expert guidance on immunisation schedules. The Serum Institute of India (SII) is the world’s largest vaccine manufacturer by volume, supplying both domestic and international markets. The World Health Organization (WHO) offers global guidelines and certification for disease eradication and elimination.

• MoHFW: Policy formulation and nationwide implementation.
• ICMR: Vaccine R&D and clinical evaluation.
• CDSCO: Regulatory authority for vaccine approval.
• NTAGI: Technical advisory on immunisation schedules.
• SII: Largest global vaccine producer by volume.
• WHO: Global immunisation standards and disease certification.

Impact and Data on Disease Eradication and Immunisation Coverage

India has achieved significant milestones in vaccine-preventable diseases. Smallpox was eradicated in India by 1977, with global eradication certified by WHO in 1980. The last polio case was reported in 2011, and WHO declared India polio-free in 2014. Maternal and neonatal tetanus was eliminated in 2015 as per WHO verification. The National Family Health Survey-5 (2019-21) reported over 90% immunisation coverage for key vaccines under UIP. India administered more than 200 crore COVID-19 vaccine doses by end-2023, contributing to global pandemic control.

• Smallpox eradication: India, 1977; WHO global certification, 1980.
• Polio elimination: Last case 2011; WHO declared polio-free 2014.
• Maternal & neonatal tetanus: Eliminated in 2015 (WHO verification).
• Immunisation coverage: >90% for key vaccines (NFHS-5).
• COVID-19 vaccination: >200 crore doses administered (MoHFW, 2023).

Comparative Analysis: India vs Nigeria on Polio Eradication

India’s success in eradicating polio contrasts sharply with Nigeria, which continues to report cases due to vaccine hesitancy and weaker cold chain infrastructure. India’s Pulse Polio Programme employed extensive community engagement, door-to-door campaigns, and robust cold chain logistics, overcoming challenges posed by its vast population and geographic diversity. Nigeria’s persistent polio cases highlight the consequences of infrastructural deficits and social resistance to vaccination.

Challenges and Gaps in India’s Immunisation Landscape

Despite high aggregate coverage, India faces persistent challenges in ensuring equitable vaccine access. Remote and tribal regions suffer from infrastructural deficits, including inadequate cold chain maintenance and healthcare workforce shortages. Vaccine hesitancy fueled by misinformation remains a barrier, particularly in marginalized communities. These gaps risk outbreaks of vaccine-preventable diseases and undermine national immunisation goals.

• Infrastructural deficits in remote and tribal areas.
• Cold chain maintenance challenges impacting vaccine potency.
• Vaccine hesitancy driven by misinformation and cultural factors.
• Unequal healthcare workforce distribution limiting outreach.

Significance and Way Forward

National Vaccination Day highlights India’s transformative public health journey through immunisation, demonstrating the strategic integration of policy, innovation, and global vaccine leadership. Sustaining and improving immunisation coverage requires focused efforts on infrastructure strengthening, community engagement to counter hesitancy, and leveraging India’s vaccine manufacturing capacity for domestic and global needs. Addressing inequities in vaccine access will be critical to consolidating gains and preventing disease resurgence.

• Strengthen cold chain and healthcare infrastructure in underserved areas.
• Enhance community-level awareness and counter misinformation.
• Leverage indigenous vaccine production for affordable access.
• Maintain robust surveillance and rapid response to outbreaks.

Jharkhand & JPSC Relevance

• JPSC Paper: Paper 2 - Health and Family Welfare; Paper 3 - Science and Technology in Health
• Jharkhand Angle: Tribal and remote areas in Jharkhand face vaccine access challenges similar to national gaps; cold chain infrastructure and awareness campaigns are critical.
• Mains Pointer: Emphasise state-specific immunisation coverage data, challenges in tribal districts, and government initiatives to improve vaccine outreach.